Published in Best Pract Res Clin Haematol on January 01, 2005
Biosimilar therapeutics-what do we need to consider? NDT Plus (2009) 1.99
Anti-erythropoietin antibodies followed by endogenous erythropoietin production in a dialysis patient. Pediatr Nephrol (2010) 1.39
Feasibility of a multiplex flow cytometric bead immunoassay for detection of anti-epoetin alfa antibodies. Clin Vaccine Immunol (2007) 0.85
Recombinant murine growth hormone particles are more immunogenic with intravenous than subcutaneous administration. J Pharm Sci (2013) 0.81
Is the decision on the use of biosimilar growth hormone based on high quality scientific evidence? - a systematic review. Eur J Clin Pharmacol (2014) 0.77
Erythropoietin improves the healing of skin necrosis resulting from Doxorubicin extravasation in a rat model. Curr Ther Res Clin Exp (2011) 0.75
Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis (2008) 15.04
Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int (2005) 10.42
Predictive performance of the modification of diet in renal disease and Cockcroft-Gault equations for estimating renal function. J Am Soc Nephrol (2005) 5.99
Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med (2010) 5.48
A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med (2009) 3.37
Timing of onset of CKD-related metabolic complications. J Am Soc Nephrol (2008) 2.60
Fanconi syndrome and renal failure induced by tenofovir: a first case report. Am J Kidney Dis (2002) 2.41
Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion (2008) 1.73
Scleraxis and NFATc regulate the expression of the pro-alpha1(I) collagen gene in tendon fibroblasts. J Biol Chem (2007) 1.72
Hemoglobin stability in patients with anemia, CKD, and type 2 diabetes: an analysis of the TREAT (Trial to Reduce Cardiovascular Events With Aranesp Therapy) placebo arm. Am J Kidney Dis (2012) 1.38
The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int (2005) 1.31
Pure red cell aplasia induced by erythropoiesis-stimulating agents. Clin J Am Soc Nephrol (2008) 1.11
Erythropoietin receptors: their role beyond erythropoiesis. Nephrol Dial Transplant (2005) 0.97
Sensitization from transfusion in patients awaiting primary kidney transplant. Nephrol Dial Transplant (2013) 0.90
Re-challenging patients who developed pure red cell aplasia with epoetin: can it be done? Nephrol Dial Transplant (2004) 0.89
Red blood cell transfusions and the risk of allosensitization in patients awaiting primary kidney transplantation. Transplantation (2014) 0.83
The new Mayo Clinic equation for estimating glomerular filtration rate. Ann Intern Med (2005) 0.82
Transcriptional control of epithelial differentiation during kidney development. J Am Soc Nephrol (2003) 0.82
Epoetin treatment: what are the arguments to expect a beneficial effect on renal disease progression? Nephrol Dial Transplant (2002) 0.78
Renewal of FSP1: a marker of fibrogenesis on human renal biopsies. Kidney Int (2005) 0.75
Renal cortical necrosis related to paraneoplastic antiphospholipid syndrome. Am J Kidney Dis (2006) 0.75